Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Anna Marie Wagner - SVP, Corporate Development Jason Kelly - Co-Founder & CEO Mark Dmytruk - CFO Conference Call Participants Matthew Sykes - Goldman Sachs Rahul Sarugaser - Raymond James Tejas Savant - Morgan Stanley Steve Mah - Cowen Madeline - William Blair Mark Massaro - BTIG Anna Marie Wagner Good afternoon. This is Anna Marie Wagner, SVP of Corporate Development at Ginkgo Bioworks.

Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2022 Earnings Call Transcript

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q4 Loss, Tops Revenue Estimates

$478 million of total revenue in 2022, representing an increase of 52% over 2021 and toward the high end of guidance 59 new Cell Programs added in 2022, representing 90% growth over 2021 and toward the high end of guidance Year end cash balance of over $1.3 billion provides meaningful multi-year runway as we drive towards profitability BOSTON , March 1, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2022. The update, including a webcast slide presentation with additional details on the fourth quarter and supplemental financial information, will be available at investors.ginkgobioworks.com.

Ginkgo Bioworks Reports Fourth Quarter and Full Year 2022 Financial Results

Few biotechs can claim to be using AI in as central of a role as Ginkgo Bioworks.

This Biotech Is Already Using AI, but Is the Growth Stock a Buy?

Ginkgo is on track to easily beat its guidance for 2022. But what about its bottom line?

Is It Too Early to Invest in Ginkgo Bioworks?

Presentation and Q&A session scheduled for post-market on Wednesday, March 1, 2023 BOSTON , Feb. 22, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2022, on Wednesday, March 1, 2023, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at  https://investors.ginkgobioworks.com/events , and a replay will be made available.

Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2022 Results Presentation

NEW YORK--(BUSINESS WIRE)---- $DNA #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Soaring Eagle Acquisition Corp., which merged with Ginkgo Bioworks Holdings Inc. ("Ginkgo" or "the Company") (NYSE: DNA) on September 17, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/dna.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Ginkgo Bioworks Holdings Inc. (DNA) Investigation

CRISPR Therapeutics

Both are on the verge of fast growth, and they haven't had any major setbacks yet.

2 Bruised Growth Stocks to Buy While They're Cheap

Amyris

Twist Bioscience Corp

Since the biotech bonanza of the pandemic era, many biotech stocks have rocketed up and then down in price. Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS ) all fell more than 75% from peak to trough, and may still have farther to fall.

The Next Big Disruptors? 3 Biotech Stocks Making Headlines.

DURHAM, N.C. and BOSTON , Feb. 16, 2023 /PRNewswire/ -- Zymtronix, a developer of cell-free process technologies, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to optimize enzymes used in Zymtronix's proprietary cell-free platform for the production of important ingredients in food, agriculture, cosmetics and pharmaceuticals.

Zymtronix and Ginkgo Bioworks Announce Partnership to Produce Enzymes for the Industrialization of Cell-Free Biomanufacturing

The program establishes a new node in a global early warning network for emerging variants to support timely and targeted public health response BOSTON and KIGALI, Rwanda , Feb. 15, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Rwanda Biomedical Centre (RBC) today announced a one-year pathogen monitoring program at Rwanda's Kigali International Airport (KGL) to identify new and emerging variants of SARS-CoV-2. Through this program, Ginkgo's biosecurity and public health unit, Concentric by Ginkgo , will collaborate with RBC to monitor wastewater samples from arriving aircraft and nasal swab samples, collected on a voluntary, anonymous basis from arriving international travelers, for SARS-CoV-2.

Ginkgo Bioworks Announces Pathogen Monitoring Program at Kigali International Airport

the next time you think Salmonella, think Prokarium. These bacteria may cause food poisoning in one form, but engineered the right way can become living medicine — turning not fuel into fire but fire into fuel.

Microbial Immunotherapy Company Prokarium Raises $30M On Heels Of Ginkgo Bioworks Partnership

Ginkgo is working to standardize its offerings and streamline the sales process by establishing an easily accessible set of offerings, standardizing key aspects. So far, the financial results showed growth and diversification in the cell programming business, with 15 new cell programs added to the platform.

Ginkgo: Standardizing Offerings For Growth

COMPASS Pathways

Intellia Therapeutics

These stocks are risky. But they just might deliver huge gains if analysts are right.

3 Cathie Wood Stocks That Could More Than Double in 12 Months, According to Wall Street

NEW YORK--( BUSINESS WIRE )--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) on behalf of long-term stockholders following a class action complaint that was filed against Ginkgo Bioworks with a Class Period from May 11, 2021 to October 5, 2021. Our investigation concerns whether the board of directors of Ginkgo Bioworks have breached their fiduciary duties to the company.

GINKGO BIOWORKS ALERT: Bragar Eagel & Squire, P.C. is Investigating Ginkgo Bioworks Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Enzymes are a multi-billion dollar market and growing. But engineering enzymes is not an easy task.

Ginkgo Bioworks Fires Up Its Bio Foundry To Take On The Billion-Dollar Enzyme Market

Ginkgo will develop and optimize strains to produce functional oligosaccharides for NAMUH's infant nutrition products BOSTON , Jan. 18, 2023 /PRNewswire/ -- NAMUH, an infant nutrition company, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a multi-product collaboration to develop functional oligosaccharides that are structurally identical to those found in human breast milk. NAMUH's mission is to create complete infant formula products substantially comparable to human breast milk, down to the molecular level.

NAMUH and Ginkgo Bioworks Announce Partnership to Produce Multiple Infant Nutrition Products

The collaboration will launch a pilot program for wastewater-based pathogen monitoring to support critical public health needs BOSTON and KYIV, Ukraine , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Public Health Center of the Ukraine Ministry of Health today announced a new collaboration to conduct a wastewater testing pilot program in Ukraine with the intent to help provide early warning for infectious disease outbreaks and enable rapid and strategic public health intervention. Amidst the ongoing COVID-19 pandemic and the strain on health infrastructure in Ukraine due to the war, the risk of infectious diseases spreading in the country has increased.

Ginkgo Bioworks and the Public Health Center of the Ukraine Ministry of Health Announce Collaboration to Implement Biosecurity Capabilities in Ukraine

XWELL Inc

The program is an effective early warning system for viral variants, leveraging voluntary sampling from international travelers at major U.S. airports BOSTON and NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) and XWELL, Inc. (Nasdaq: XWEL) today announced that they have expanded their support for the Centers for Disease Control and Prevention's (CDC's) Traveler-based Genomic Surveillance program to include a pilot study monitoring influenza viruses in addition to SARS-CoV-2. The partners continue to grow the program's capabilities to provide an additional source of viral surveillance to inform the selection of influenza vaccine viruses for the forthcoming 2023-2024 flu season.

Ginkgo Bioworks and XpresCheck Expand CDC's Traveler-Based Genomic Surveillance Program to Detect Influenza Variants

Aytu BioScience

PLBY Group

Sana Biotechnology

Short squeeze penny stocks to watch this month. The post 4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?

4 Short Squeeze Penny Stocks To Watch In January 2023; Time To Buy?

Expects to meet 2022 guidance ranges for Total revenue and new Cell Programs Year end cash balance of approximately $1.3 billion provides ample liquidity and puts Ginkgo in a position of strength to continue to build its leadership position despite a challenging macroenvironment Strong growth among biopharma customers as Ginkgo has scaled its mammalian cell engineering capabilities, including recently opening Bioworks7, which is fully dedicated to mammalian cell engineering workflows Management to highlight updates today at the 41st Annual J.P. Morgan Healthcare Conference at 11:15 a.m.

Ginkgo Bioworks Provides Preliminary Unaudited 2022 Revenue Highlights and Business Review

LONDON and BOSTON , Jan. 9, 2023 /PRNewswire/ -- Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop a bactofection platform to deliver RNA-based therapeutics. Most gene therapies today leverage viral delivery systems.

Prokarium and Ginkgo Bioworks Announce Partnership to Discover Multiple Targets for RNA Therapeutics and Immuno-oncology

Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications BOSTON , Jan. 6, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced the opening of Bioworks7, the latest expansion of its biological engineering foundry. With this new space, Ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities.

Ginkgo Bioworks Expands Its R&D Facilities, Opens Bioworks7 to Conduct Mammalian Screening at Scale, Widening Capabilities for Biopharma Partners

Initial focus of partnership will aim to develop cancer therapeutics PLYMOUTH, Mich. and BOSTON , Jan. 5, 2023 /PRNewswire/ -- Esperovax, an innovative developer of oral mRNA biologics, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.

Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

BOSTON , Jan. 4, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, announced today that Co-Founder and CEO Jason Kelly is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 11:15 a.m.

News for Ginkgo Bioworks Holdings Stock (DNA)